Table 3.
Impact of Graffar score and femoral nucleus diameter on long-term neurodevelopmental outcomes.
| Graffar score | Femoral nucleus diameter | |
|---|---|---|
| 24 months | ||
| Developmental quotient | 1.39 (1.07 to 2.02) p=0.04 | 0.8 (0.56 to 1.12) p=0.2 |
| Subscale A | 1.1 (0.89 to 1.42) p=0.43 | 0.62 (0.39 to 0.91) p=0.02 |
| Subscale B | 1.34 (1.1 to 1.73) p=0.01 | 0.71 (0.52 to 0.94) p=0.02 |
| Subscale C | 1.05 (0.91 to 1.21) p=0.54 | 0.98 (0.77 to 1.26) p=0.89 |
| Subscale D | 1.57 (1.11 to 2.64) p=0.04 | 0.75 (0.49 to 1.1) p=0.16 |
| Subscale E | 1.18 (0.94 to 1.61) p=0.2 | 1.06 (0.72 to 1.62) p=0.77 |
| 48 months | ||
| Total Intelligence Quotient | 1.51 (1.07 to 2.54) p=0.05 | 0.62 (0.38 to 0.92) p=0.03 |
| Verbal Intelligence Quotient | 1.26 (0.99 to 1.74) p=0.1 | 0.8 (0.54 to 1.13) p=0.21 |
| Performance Intelligence Quotient | 1.51 (1.07 to 2.54) p=0.05 | 0.62 (0.38 to 0.92) p=0.03 |
| Processing Speed Quotient | 1.72 (1.19 to 2.95) p=0.02 | 0.66 (0.43 to 0.93) p=0.03 |
Data are expressed as Odds Ratio for having a long-term neurodevelopmental outcome lower than clinical threshold (<85 point) for every unit increase in Graffar score or femoral nucleus. Results were obtained using univariable logistic regression models. Bold values has been used to underline the results but it is not necessary.